-Reuters
Chemomab Therapeutics reports Expanded Partnership With AGC Biologics To Manufacture CM-101 For Phase 2/3
AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility
TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage